All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 700+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Takeda rare blood disease enzyme replacement therapy approved in Europe
Enzyme replacement therapy, congenital thrombotic thrombocytopenic purpura - Read more

Diality’s hemodialysis system lands FDA approval
Medical device, hemodialysis, renal failure, kidney failure - Read more

THE GOOD
Business Development

Chugai acquires Japan rights to Roche IBD antibody med
Monoclonal antibody, inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease - Read more

THE GOOD
Clinical Trials

Sumitomo Pharma, Poxel tout positive post-marketing study for type 2 diabetes-related renal impairment med
Small molecule, type 2 diabetes, renal impairment - Read more

Stoke Therapeutics stoked as FDA releases partial clinical hold on their Dravet syndrome med, opening path to Ph3
Antisense oligonucleotide, Dravet syndrome - Read more

Tr1x Bio’s IND cleared by FDA
Treg cell therapy, Crohn’s disease - Read more

THE GOOD
Earnings & Finances

Amgen’s $27.8B Horizon acquisition was a good idea, continues to deliver healthy growth through Q2 2024 - Read more

Madrigal Pharmaceuticals’ MASH med mashed the commercial gas as Q2 earnings fly past analyst expectations
Small molecule, metabolic dysfunction-associated steatohepatitis - Read more

Merck KGaA optimistic about CDMO business recovery, despite continued decline
CDMO, manufacturing - Read more

THE GOOD
Fundraises

IDRx $120M Series B
Small molecule, gastrointestinal stromal tumours - Read more

Nammi Therapeutics $30M Series B
Antibody, solid tumor, myeloma, cancer - Read more

Quantro Therapeutics receives Austrian research grant
Transcriptomic drug discovery, R&D - Read more

PRESENTED BY THE UBC SCHOOL OF BIOMEDICAL ENGINEERING
Today’s Ideas. Tomorrow’s Solutions.

Driving innovation in Canada’s biotech and life sciences sectors requires a complex and specialized skill set. The UBC Micro-certificate in Innovation Leadership: Medical & Bio-Innovations equips professionals with the practical, legal, and strategic skills needed to translate technological and scientific innovations into improved patient outcomes and healthcare impacts.

Learn how to identify and address unmet patient needs while implementing intellectual property strategies that protect and leverage healthcare innovations. Gain relevant, in-demand skills from a diverse panel of industry experts, which you can apply immediately in your professional role or organization.

Course enrolment is now open. Learn more and register today!

⬇️ The Good News (Cont’d) ⬇️

THE GOOD
Investments

Canada invests CAD$22.4M ($16.3M) in Eurofins Alphora site
CDMO, biopharma manufacturing, biologics, clinical testing - Read more

BioGlyph’s minority investment from Dotmatics
Biologic molecule modelling, multispecific antibody - Read more

THE GOOD
Mergers & Acquisitions

Pharmacosmos buys G1 Therapeutics for $405M
Small molecule, lung cancer, breast cancer - Read more

THE GOOD
Partnerships

Formosa Pharmaceuticals, Eyenovia dry eye disease co-development partnership
Small molecule, dry eye disease - Read more

THE GOOD
Patient Access

Genentech, American Diabetes Association launch vision screening and care program to diabetes patients in under-resourced communities - Read more

THE GOOD
Regulatory

FDA continues to debate how to deal with AI and it’s continued industry adoption - Read more [Paywall]

THE GOOD
Strategic Plans

Aeterna Zentari rebrands to COSCIENS Biopharma
Small molecule, botanical research products, adult growth hormone deficiency - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Approvals & Labels

Novo Nordisk pulls back FDA submission for Wegovy heart failure label expansion
GLP-1, obesity, heart failure - Read more

BeiGene’s first-line Tevimbra label expansion decision delayed by FDA due to delayed clinical site inspections
Monoclonal antibody, carcinoma, cancer - Read more [Paywall]

THE BAD
Clinical Trials

Exelixis drops ADC after disappointing Ph1 interim results
Antibody-drug conjugate, solid tumor, cervical cancer - Read more

THE BAD
Earnings & Finances

Novo Nordisk Q2 sales slump due to semaglutide slowdown
GLP-1, obesity, diabetes - Read more

Illumina sees lowered service and instrument sales in Q2 amidst softening market conditions, particularly in China
Sequencing, instrumentation - Read more

Evotec shares crater after “profit warning” - Read more

THE BAD
Layoffs

Precigen restructures, cuts multiple CAR-T programs and lays off 20% of their staff
CAR-T cell therapy, leukaemia, cancer - Read more

THE BAD
Strategic Plans

Novo Nordisk drops multiple clinical prospects, including once-monthly GLP-1/GIP agonist and MASH candidate
GLP-1/GIP, obesity, metabolic dysfunction-associated steatohepatitis - Read more

Roche (allegedly) considers divesting Flatiron Health division
Cancer care infrastructure, cancer data - Read more

Relay Therapeutics ditches migoprotafib (cancer asset) after Genentech ditches development partnership
Small molecule, cancer - Read more

THE UGLY
Criminal Acts

Former Pfizer convicted on insider trading related to Paxlovid
Insider trading - Read more [Paywall]

THE UGLY
Lawsuits

University of Pennsylvania sues BioNTech over alleged COVID-19 royalties
mRNA, COVID-19 vaccine - Read more

THE UGLY
Regulatory

FDA roasts Bristol Myers Squibb on “misleading” Krazati efficacy claims
Small molecule, lung cancer, drug website - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.